Johnson & Johnson (JNJ) Stock Surges Following Strong Q1 2026 Earnings Report

Key Highlights

• The healthcare giant delivered Q1 adjusted earnings of $2.70 per share, surpassing the Street’s $2.68 projection, while revenue hit $24.1 billion versus $23.6 billion anticipated.
• The pharmaceutical segment jumped 11.2% from the prior year to $15.4 billion, fueled by blockbuster drugs Darzalex ($4.0B) and Tremfya ($1.6B).
• Management boosted 2026 full-year revenue projections to $100.8 billion and lifted adjusted earnings guidance to $11.55 per share.
• Newly approved psoriasis treatment Icotyde has potential to generate approximately $10 billion in peak annual sales, according to Truist Securities estimates.
• Shares of JNJ have climbed 15% since the start of 2026, significantly outperforming the S&P 500’s 0.6-1% increase.

Johnson & Johnson unveiled its first-quarter 2026 financial results Tuesday morning, delivering both revenue and profit figures that exceeded Wall Street projections.

Revenue reached $24.1 billion, representing a 10% increase compared to the corresponding quarter last year and topping the analyst consensus of $23.6 billion tracked by FactSet. The company’s adjusted profit per share landed at $2.70, marginally beating the expected $2.68.

Shares climbed approximately 1.2% during pre-market hours after the earnings release.

Johnson & Johnson, JNJ

The results cap a transformative period for J&J. Over recent years, the healthcare conglomerate has strategically pivoted from consumer health offerings — including the spinoff of Kenvue, currently being purchased by Kimberly-Clark — to sharpen its focus on the pharmaceutical and medical technology sectors.

The pharmaceutical arm stood out as the quarter’s star performer, climbing 11.2% from the year-ago period to reach $15.4 billion. This handily exceeded the FactSet projection of $15.2 billion.

Darzalex, the company’s flagship multiple myeloma treatment, generated $4.0 billion during the quarter, a substantial increase from $3.2 billion in the prior-year period. Analysts had forecast $3.9 billion.

Tremfya, an IL-23 blocking agent for autoimmune diseases, delivered $1.6 billion in quarterly sales, jumping from $956 million twelve months earlier and surpassing the $1.4 billion consensus.

Strengthening Position in Immunology

Regulators granted approval for Tremfya’s subcutaneous formulation last September for ulcerative colitis and Crohn’s disease patients, establishing it as the first medication in its category allowing home self-administration. This provides a competitive edge versus AbbVie’s Skyrizi, which necessitates clinic-based initial infusions.

Additionally, J&J secured FDA clearance in the previous month for Icotyde, an innovative oral IL-23 inhibitor tablet for plaque psoriasis, originating from a 2017 licensing arrangement with Protagonist Therapeutics. Truist Securities analyst Srikripa Devarakonda projects Icotyde could ultimately achieve peak annual revenues approaching $10 billion. The company hasn’t yet reported any commercial sales data.

The medical technology segment contributed $8.6 billion in revenue, matching analyst expectations.

Net profit totaled $5.2 billion, falling short of the FactSet projection of $6.5 billion — marking the second straight quarter where bottom-line earnings missed forecasts.

Updated Outlook and Ongoing Litigation

Looking ahead to the complete year, J&J elevated its revenue forecast to $100.8 billion from the previous $100.5 billion target. The adjusted earnings per share outlook was raised to $11.55 from $11.03. Wall Street had anticipated $11.54 per share and $100.6 billion in revenue.

The corporation continues managing significant legal challenges. As of Q4 2025, J&J confronted 74,360 pending lawsuits alleging it deliberately marketed talcum powder products contaminated with carcinogenic asbestos. Its latest effort to settle these claims through a bankruptcy proceeding involving subsidiary Red River Talc was rejected by a Texas court, permitting individual cases to move forward.

J&J continues asserting that its baby powder, currently marketed under the Kenvue label, remains safe and free from asbestos contamination.

Among 29 analyst firms monitored by FactSet, 17 assign JNJ a Buy rating or similar positive recommendation. Two analysts rate it a Sell.

JNJ stock has advanced 15% year-to-date in 2026, substantially outpacing the S&P 500’s gain of approximately 0.6% to 1% during the identical timeframe.